Linc AB

Equities

LINC

SE0015949433

Investment Management & Fund Operators

Market Closed - Nasdaq Stockholm Other stock markets 06:59:46 2024-04-30 am EDT			5-day change	1st Jan Change
68.6 ^SEK	+0.15%		+5.54%	+6.19%

Apr. 22	Linc AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 25	Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

February 07, 2022 at 01:00 am EST

Linc AB reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was SEK 34.27 million compared to SEK 417.3 million a year ago. Net income was SEK 17.16 million compared to SEK 352.16 million a year ago.

Basic earnings per share from continuing operations was SEK 0.3 compared to SEK 8.8 a year ago.

Latest news about Linc AB

Linc AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 25	CI
Linc AB Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI
Linc AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Linc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-20	CI
Linc AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-20	CI
Linc AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-08	CI
Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-08	CI
Akiram Therapeutics AB announced that it has received SEK 68 million in funding from Sciety AB, Linc AB	23-01-11	CI
MedCap AB (OM:MCAP) made a tender offer to acquire AdderaCare AB (OM:ADDERA) from a group of shareholders and others for approximately SEK 120 million on November 17, 2022.	23-01-08	CI
MedCap AB (OM:MCAP) made a tender offer to acquire AdderaCare AB (OM:ADDERA) from a group of shareholders and others for approximately SEK 120 million.	22-11-16	CI
Linc AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-20	CI
Alder Therapeutics announced that it has received SEK 20 million in funding from Flerie Invest AB, Linc AB	22-09-26	CI
Linc AB(OM:LINC) dropped from S&P Global BMI Index	22-09-19	CI
MWI Veterinary Supply, Inc. acquired Swevet AB from Linc AB (OM:LINC).	22-08-30	CI
Linc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-20	CI
Certain Ordinary Shares of Linc AB are subject to a Lock-Up Agreement Ending on 24-MAY-2022.	22-05-23	CI
Cinclus Pharma Holding AB announced that it has received SEK 240 million in funding from Trill Impact AB, Eir Ventures, Irrus Investments Nominee Limited, AP Fonden 4, Linc AB	22-05-19	CI
Linc AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-20	CI
Cinclus Pharma Holding AB announced that it expects to receive SEK 240 million in funding from Trill Impact AB, Eir Ventures, Irrus Investments Nominee Limited, AP Fonden 4, Linc AB	22-04-18	CI
Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB	22-04-12	CI
Linc AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-07	CI
Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-07	CI
Oncorena AB announced that it has received SEK 66 million in funding from Fahraeus Startup & Growth Ab, Linc AB, Odlander, Fredrikson & Co. AB	21-12-22	CI
Linc AB(OM:LINC) added to S&P Global BMI Index	21-12-20	CI

Chart Linc AB

Duration

Period

More charts

Company Profile

Linc Invest AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.

Sector

Investment Management & Fund Operators

Calendar

2024-07-17 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Hedge Funds

	1st Jan change	Capi.
LINC AB	+6.19%	363M
CADENCE CAPITAL LIMITED	+2.49%	140M

Hedge Funds